EA201590244A1 - METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSIS - Google Patents
METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSISInfo
- Publication number
- EA201590244A1 EA201590244A1 EA201590244A EA201590244A EA201590244A1 EA 201590244 A1 EA201590244 A1 EA 201590244A1 EA 201590244 A EA201590244 A EA 201590244A EA 201590244 A EA201590244 A EA 201590244A EA 201590244 A1 EA201590244 A1 EA 201590244A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- agent
- treating tuberculosis
- solution
- tuberculosis
- manufacturing
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title abstract 6
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- 229940113720 aminosalicylate Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 238000009738 saturating Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Способ изготовления средства для лечения туберкулеза принадлежит к химико-фармацевтической промышленности и медицине, в частности к способам изготовления средств для лечения туберкулеза в виде растворов для инфузий. Способ изготовления средства для лечения туберкулеза включает такие действия, как растворение в воде динатриевой соли этилендиаминтетрауксусной кислоты и натрия сернистокислого безводного, последующее растворение натрия парааминосалицилата, доведение объема раствора до необходимого путем добавления воды, насыщение раствора азотом, добавление гидроксида натрия до получения необходимой величины рН раствора. Способ изготовления средства для лечения туберкулеза позволяет получить продукт, который имеет стабильность свойств и необходимый уровень качества средства для лечения туберкулеза в процессе его хранения в течение 1-1,5 лет при температурах, которые не отличаются от комнатных.A method of manufacturing an agent for treating tuberculosis belongs to the chemical and pharmaceutical industry and medicine, in particular to methods for producing an agent for treating tuberculosis in the form of solutions for infusions. A method of making an agent for treating tuberculosis includes actions such as dissolving the disodium salt of ethylenediaminetetraacetic acid and sodium anhydrous sulfuric acid in water, then dissolving sodium para-aminosalicylate, adjusting the solution to the required amount by adding water, saturating the solution with nitrogen, adding sodium hydroxide to obtain the required solution pH . A method of manufacturing an agent for treating tuberculosis makes it possible to obtain a product that has the stability of properties and the required level of quality of an agent for treating tuberculosis during its storage for 1-1.5 years at temperatures that do not differ from room temperature.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAU201209117U UA74097U (en) | 2012-07-24 | 2012-07-24 | Method for manufacturing drug for treatment of tuberculosis |
PCT/UA2013/000080 WO2014017999A1 (en) | 2012-07-24 | 2013-07-22 | Method for producing an agent for the treatment of tuberculosis |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201590244A1 true EA201590244A1 (en) | 2015-06-30 |
EA028883B1 EA028883B1 (en) | 2018-01-31 |
Family
ID=49997650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590244A EA028883B1 (en) | 2012-07-24 | 2013-07-22 | Method for producing an agent for the treatment of tuberculosis |
Country Status (6)
Country | Link |
---|---|
AP (1) | AP2015008271A0 (en) |
BR (1) | BR112015001674A2 (en) |
EA (1) | EA028883B1 (en) |
RU (1) | RU2015106365A (en) |
UA (1) | UA74097U (en) |
WO (1) | WO2014017999A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265475B (en) * | 2020-02-28 | 2024-01-02 | 天津金耀药业有限公司 | Isoniazid injection and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4233842A1 (en) * | 1992-10-08 | 1994-04-14 | Asta Medica Ag | Mesna injection solutions |
UA58983U (en) * | 2010-11-15 | 2011-04-26 | Наталья Николаевна Деркач | Method for manufacturing composition for treating tuberculosis |
-
2012
- 2012-07-24 UA UAU201209117U patent/UA74097U/en unknown
-
2013
- 2013-07-22 EA EA201590244A patent/EA028883B1/en not_active IP Right Cessation
- 2013-07-22 BR BR112015001674A patent/BR112015001674A2/en not_active IP Right Cessation
- 2013-07-22 RU RU2015106365A patent/RU2015106365A/en unknown
- 2013-07-22 AP AP2015008271A patent/AP2015008271A0/en unknown
- 2013-07-22 WO PCT/UA2013/000080 patent/WO2014017999A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2014017999A1 (en) | 2014-01-30 |
AP2015008271A0 (en) | 2015-02-28 |
BR112015001674A2 (en) | 2017-08-08 |
RU2015106365A (en) | 2016-09-10 |
UA74097U (en) | 2012-10-10 |
EA028883B1 (en) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130181A1 (en) | PROCEDURE FOR THE PREPARATION OF 4- {4 - [({[4-CHLORO-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] -3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND ITS MONOHYDRATE | |
PL412787A1 (en) | Macrophage-based aimed system for delivery of ferritin related compounds | |
UA113981C2 (en) | Ophthalmic solution containing diquafasol | |
MX2021013880A (en) | Proton-binding polymers for oral administration. | |
BR112015026473A2 (en) | formulation of a contrast medium and its associated preparation process | |
MX2017016189A (en) | Chelating base product for use in water-based system treatments and method of making base product. | |
GB2500128A (en) | Colonoscopy-preparation | |
AR098798A1 (en) | PROCEDURE FOR THE DIAZOTIZATION OF 2,5-DICLOROANILINES | |
MX2015016424A (en) | Aqueous solutions containing a complexing agent in high concentration. | |
MX2015016057A (en) | Stabilized hypochlorous acid solution and use thereof. | |
PH12016500913A1 (en) | Soap bar | |
EA201590244A1 (en) | METHOD OF MAKING MEANS FOR THE TREATMENT OF TUBERCULOSIS | |
EA201691825A1 (en) | STABILIZED SOLUTION ON THE BASIS OF ACTIVE SUBSTANCES, METHOD FOR OBTAINING A STABILIZED SOLUTION OF ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITION ON THE BASIS OF A STABILIZED SOLUTION OF ACTIVE SUBSTANCES (TWO OPTIONS) | |
MY160461A (en) | Process for producing granules comprising one or more complexing agent salts | |
EA201391595A1 (en) | NEW METALLOPROTEIN, METHOD FOR ITS OBTAINING AND PROPHYLACTIC OR THERAPEUTIC AGENT IN HYDROUS DISEASES OR CONJUNCTION CONTAINING METABLE PROTEIN | |
EA201491767A1 (en) | METHOD AND INSTALLATION FOR THE PRODUCTION OF SOLUTIONS OF NONLINK AGENTS | |
PL420099A1 (en) | Method for production of alpha-ketoglutaric acid (AKG) from one-component water solutions | |
WO2014140899A3 (en) | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain | |
RU2013152987A (en) | METHOD FOR PRODUCING TETRACHLOROPLOATE (II) -ION ION AND ITS SALTS WITH SODIUM, POTASSIUM OR AMMONIUM | |
RU2013107097A (en) | METHOD FOR PRODUCING CIS-Dichlorodiammine Platinum (II) | |
UA105830C2 (en) | Method for the preparation of agent for tuberculosis treatment and agent prepared by the method | |
PL410425A1 (en) | New alkoxymethyl di(2-hydroxyethyl)methylammonium ionic liquids with sweet anion and method for producing them | |
RU2013133363A (en) | METHOD FOR PREVENTION OF DAMAGE TO BIOLOGICAL MEMBRANES | |
RU2014114107A (en) | METHOD FOR PRODUCING COLLOIDAL SOLUTION OF LEAD SULPHIDE NANOPARTICLES | |
FI20105036A0 (en) | Process for preparing a carbamate cellulose solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |